Leicester research team receives €6.5 million for EURO SHOCK heart attack study

Posted by ap507 at Dec 13, 2017 09:35 AM |
Project led by University of Leicester and Leicester’s Hospitals to examine the effectiveness of using ‘artificial’ heart and lungs following heart attacks

Issued by University of Leicester on 13 December 2017

An image of Professor Anthony Gershlick is available here: https://www.dropbox.com/sh/pu03yxttspk0ckd/AAD86uCGPmOZCyZ7EeFNqZ5Ea?dl=0

A team of researchers at the NIHR Leicester Biomedical Research Centre, UK - a partnership between Leicester’s Hospitals, the University of Leicester and Loughborough University - has been awarded €6.5 million from the Horizon 2020 European Commission fund.

The team, led by clinical scientist consultant Professor Anthony Gershlick from the University’s Department of Cardiovascular Sciences, will investigate the impact of using Extracorporeal Membrane Oxygenation (ECMO) on the outcomes of patients who have had a severe heart attack.

ECMO is a machine that acts as an artificial heart and lungs to provide oxygen to the blood and remove waste gases. The blood is pumped using a motor. This allows the patient’s heart and lungs the time to rest and repair themselves.

Professor Gershlick, Professor of Interventional Cardiology at the University of Leicester and Consultant Cardiologist at Leicester’s Hospitals, explained: “Between 8-10% percent of patients who have heart attacks suffer from cardiogenic shock, such that their hearts fail to pump properly. In such cases, the mortality rate can be as high as 50 percent in the first 3 months after the heart attack. ECMO is sometimes used to treat these patients, but it is often deployed too late and their heart is already very weak. We will investigate whether using ECMO on patients that suffer from cardiogenic shock immediately after their heart attack will reduce mortality rates and improve their outcomes. There has been world-wide interest in our proposal especially from the USA. There will be a number of sub-studies that could have far reaching impact on other groups of unwell patients, such as specific MRI proposals.”

Leicester will be the lead centre, coordinating the study in 11 other sites across Europe, including Germany, Norway and Spain.

Professor Philip Baker, Pro-Vice-Chancellor and Head of the College of Life Sciences at the University of Leicester, said: “This award is a fantastic achievement. Professor Gershlick has done remarkably well to secure funding for this large and important trial led from Leicester. Despite the uncertainties in European funding, the College of Life Sciences at the University of Leicester has been extremely successful in obtaining European funding for Biomedical Research. This award is a further example of Leicester’s success in leading transformative Medical Research.”

John Adler, Chief Executive of Leicester’s Hospitals, said: “We are thrilled that Leicester has been recognised as a centre of excellence for cardiac research in Europe through the Horizon 2020 research and innovation programme. Across Europe, more than 4 million people lose their lives to heart failure so Professor Gershlick’s study to test a new treatment procedure is very welcome. The ECMO unit at Leicester’s Hospitals was the first to be developed in the UK nearly 30 years ago and is currently one of the busiest in world, so we are well placed to lead such important research.”

The ECMO unit is based at Glenfield Hospital and is one of only 8 ECMO units in the country. It is the only UK site that provides ECMO for both adults and children.

This project has received funding from the European Union’s Horizon 2020 research and innovation programme under grant agreement No 754946.

Horizon 2020 is the biggest European Union Research and Innovation programme ever designed to make more breakthroughs, discoveries and world-firsts by taking great ideas from the lab to the market. It aims to ensure that Europe produces world-class science, removes barriers to innovation and makes it easier for public and private sectors to work together to create healthy societies. 


Notes for editors:

Who is taking part in the research?

EURO SHOCK unites the foremost medical doctors of cardiovascular diseases in Europe. The project involves 12 university and large public hospitals and two private companies from nine European countries. The project partners are University of Leicester (UK), Deutsches Herzzentrum München (DE), University of Glasgow (UK), Katholieke Universiteit Leuven (BE), Ludwig-Maximilians-Universität München (DE), Consorci Institut D’Investigacions Biomèdiques August Pi I Sunyer (ES), Universitetet i Tromsø (NO), Paula Stradina Liniska Universitates Slimnica AS (LV), Acienda Ospedaliera Papa Giovanni XXIII (IT), Universitair Zeikenhuis Antwerpen (BE), University of East Anglia (UK), Universitat Politècnica de Catalunya (ES), Charlice Medical Limited (UK) and Accelopment AG (CH).

The NIHR Leicester Biomedical Research Centre
The National Institute for Health Research (NIHR) Leicester Biomedical Research Centre (BRC) is a partnership between University Hospitals of Leicester NHS Trust, the University of Leicester and Loughborough University. It is funded by the National Institute for Health Research (NIHR).

The NIHR Leicester BRC undertakes translational clinical research in priority areas of high disease burden and clinical need. These include cardiovascular disease, respiratory disease, and lifestyle, obesity and physical activity. There is also a cross-cutting theme for precision medicine. The BRC harnesses the power of experimental science to explore and develop ways to help prevent and treat chronic disease. It brings together 70 highly skilled researchers, 30 of which are at the forefront of clinical services delivery. By having scientists working closely with clinicians, the BRC can deliver research that is relevant to patients and the professionals who treat them.

The National Institute for Health Research (NIHR): improving the health and wealth of the nation through research.
Established by the Department of Health, the NIHR:
•     funds high quality research to improve health
•     trains and supports health researchers
•     provides world-class research facilities
•     works with the life sciences industry and charities to benefit all
•     involves patients and the public at every step

For further information, visit the NIHR website www.nihr.ac.uk



Share this page: